The Inhibitory Effect Of LYXC On HBV In Vivo And In Vitro

Objective: To study the inhibitory effect of LYXC on duck hepatitis B virus (DHBV) in vivo and HBV in vitro,and provide an experimental basis for developing a new drug for the clinical treatment of patients with hepatitis.Methods: (1) 1-day old Guangxi brown spot ducklings infected with DHBV were used as the hepatitis B animal model. Positive ducklings were detected by PCR 13 days after the infection,and were randomly divided into five groups:Liuyuexue Compound (LYXC) high-dose group,middle-dose group, low-dose group, model group, Aciclovir control group.Every group had 10 ducklings, and LYXC was given, i.g.,for 14 days.The quantity of DHBV DNA in serum was monitored by FQ-PCR,DHBsAg and DHBeAg in serum were detected simultaneously by ELISA. ALT and AST in serum were detected before treatment(T₀),7days(T₇) and 14days(T₁₄) after treatment, 3 days after stopping treatment. Liver histopathological examination was done 3 days after stopping treatment. (2) The effect of LYXC on HBV in vitro:The TC₅₀ and TC₀ of LYXC to the HepG2.2.15 cells transfected with HBV gene was determined by MTT assay. Adding LYXC to cultured HepG2.2.15 cells by two different drug adding methods: adding directly and serum pharmacology method. HepG2.2.15 cells were cultured in medium containing different non-cellulotoxic concentration and 10% serum of LYXC. After 72h and 144h of incubation, the culture medium was collected for determining the quantity of HBV-DNA by FQ-PCR and the levels of HBsAg, HBeAg by ELISA.Results: (1) The effect of LYXC on DHBV in vivo: LYXC could significantly decrease the serum DHBV DNA,DHBsAg and DHBeAg. LYXC in the high-dose group and middle-dose group could significantly inhibit DHBV-DNA replication in vivo (P<0.05 or P<0.01), and had apparent inhibitory effect on HBsAg and HBeAg (P<0.01). At 3 days after stopping treatment, DHBV DNA, DHBsAg and DHBeAg concentrations in serum in high-dose group did not return significantly,as well as...